In a preferred embodiment with a) and b) present as active ingredients the ratio of a) to d) is from 3:1 to 1:3, more preferably from 2:1 to 1:2 and most preferred from 1.8:1 to 1:1.9. In this case d) is preferably d2) only.

In one alternative embodiment only a) is present as active ingredient, no b) is present.

In one preferred embodiment the formulation is free of water-soluble inorganic filler d1).

In one preferred embodiment the proportion of the water-soluble organic filler d2) is from 8-22 % by weight, preferably from 8 – 15 % by weight.

In another preferred embodiment, the formulation is free of water-soluble inorganic filler d1) and the proportion of the water-soluble organic filler d2) is from 8-22 % by weight, preferably from 8 – 15 % by weight.

Examples:

Preparation of WGs via extrusion as suitable process with low thermal stress:

A mixture of the low-melting active ingredient, and optionally a second active ingredient, and other starting materials (see examples) were, as known in the art, ground in a 4" air jet mill Hosokawa 100 AS (injector air 5.5 bar, grinding air 4.5 bar, throughput 100 g / min), moistened with water (about 11 wt .-%) and extruded on a Fuji Paudal Dome extruder (die size 1 mm) to a WG and post-dried in a fluidized bed dryer until a product temperature of approx. 45°C.

Flupyradifurone + Spiromesifen

Example	#1 (comparative example)	#2	#3	#4	#5	#6	#7 (comparative example)
component	**concentration [wt%]**						
Flupyradifurone	12	12	12	12	12	12	12
Spiromesifen	12	12	12	12	12	12	12
Morwet EFW	2	2	2	2	2	2	2
Morwet D-425	15	15	15	15	15	15	15